Company Overview of Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.
16745 West Bernardo Drive
San Diego, CA 92127
Founded in 2005
Key Executives for Conatus Pharmaceuticals Inc.
Co-Founder, CEO, President & Director
Total Annual Compensation: $503.8K
Co-Founder, Chief Scientific Officer and Executive VP of Research & Development
Total Annual Compensation: $386.7K
Executive Vice President of Clinical Development
Total Annual Compensation: $389.2K
Compensation as of Fiscal Year 2016.
Conatus Pharmaceuticals Inc. Key Developments
Conatus Pharmaceuticals Inc. Announces Top-Line Results from Phase 2b POLT-HCV-SVR Clinical Trial
Apr 4 18
Conatus Pharmaceuticals Inc. on April 4, 2018, announced top-line results from the company’s exploratory Phase 2b POLT-HCV-SVR proof-of-concept clinical trial in liver transplant patients with fibrosis or cirrhosis. Although the trial did not meet its primary endpoint in the heterogeneous overall trial population, the emricasan treatment effect in the subgroup of patients where the histology endpoint is most relevant, patients with advanced fibrosis and early cirrhosis, supports further evaluation. POLT-HCV-SVR has a separate patient population versus the other three Phase 2b clinical trials in the company’s collaboration with Novartis, which are in non-viral indications in patient populations with nonalcoholic steatohepatitis (NASH) fibrosis or cirrhosis. Patients were stable transplant recipients who were an average of seven years post-transplant on chronic immunosuppression. Hepatitis C virus (HCV), the initial cause of the inflammatory insult to the transplanted liver, was eliminated by antiviral therapies prior to the study. This is the first demonstration of the anti-fibrotic efficacy with emricasan using a histology endpoint in patients with fibrosis. Consistent with the previous 16 clinical trials, emricasan was generally well-tolerated in the POLT-HCV-SVR clinical trial, and the overall safety profile was similar in the emricasan and placebo groups. Emricasan provided evidence of an anti-fibrotic treatment effect in the prespecified subgroup of patients with advanced fibrosis or early cirrhosis (F3-F5 at baseline), with 95.0% of patients (19/20) in the emricasan arm achieving responses in Ishak Fibrosis Score after two years of treatment, compared with 58.3% (7/12) in the placebo arm, a 36.7 percentage point difference in response rate (p<0.02). Inflammatory activity markers (ALT, cCK18, flCK18, Knodell activity index components) were either normal or only slightly elevated at baseline in both the emricasan and placebo groups. The POLT-HCV-SVR trial, initiated in the second quarter of 2014, enrolled post-orthotopic liver transplant (POLT) recipients whose transplanted livers were damaged by recurrent HCV infection. They subsequently achieved a sustained viral response (SVR) following HCV antiviral therapy, but their transplanted livers had residual fibrosis or cirrhosis (baseline Ishak Fibrosis Score of F2 to F6). Patients were randomized 2:1 to receive 25 mg of emricasan, the company’s first-in-class, orally active pan-caspase inhibitor, or placebo, twice daily for two years. Biopsies were taken at baseline, after one year of treatment, and after two years of treatment. The primary endpoint was defined as the difference in percentage of responders between the treatment and placebo arms at the two-year biopsy compared with the baseline biopsy. A response was defined as improvement or stability in Ishak Fibrosis Score for patients with baseline scores of F2 to F5 or improvement in Ishak Fibrosis Score for patients with baseline scores of F6. The prespecified goal was a difference of 15 percentage points or more in response rates between the treatment and placebo arms. POLT-HCV-SVR studied a separate patient population versus the other three Phase 2b clinical trials in the company’s collaboration with Novartis, with the remaining three in non-viral indications – the EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) trials, designed to evaluate emricasan in patients with fibrosis or cirrhosis caused by NASH: ENCORE-PH (for Portal Hypertension), initiated in the fourth quarter of 2016, in approximately 240 patients with NASH cirrhosis and severe portal hypertension, with top-line results expected in the second half of 2018; ENCORE-NF (for NASH Fibrosis), initiated in the first quarter of 2016, in approximately 330 patients with NASH fibrosis, with top-line results expected in the first half of 2019; and ENCORE-LF (for Liver Function), initiated in the second quarter of 2017, in approximately 210 patients with decompensated NASH cirrhosis, with top-line results expected in the second half of 2019.
Conatus Pharmaceuticals Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2017
Mar 7 18
Conatus Pharmaceuticals Inc. announced unaudited earnings results for the fourth quarter and year ended December 31, 2017. For the quarter, the company reported revenue was $8,804,399 against $799,046 a year ago. Loss from operations was $4,407,504 against $9,177,689 a year ago. Net loss was $4,356,403 or $0.15 per basic and diluted share against $9,123,502 or $0.35 per basic and diluted share a year ago.
For the full year, the company reported revenue of $35,346,796 against $799,046 a year ago. Loss from operations was $17,550,484 against $29,831,768 a year ago. Net loss was $17,396,413 or $0.61 per basic and diluted share against $29,733,441 or $1.31 per basic and diluted share a year ago.
Conatus Pharmaceuticals Seeks Acquisitions
Mar 7 18
Conatus Pharmaceuticals Inc. (NasdaqGM:CNAT) is looking at ongoing pipeline expansion activities and evaluating potential in-licensing or acquisition of external clinical-stage product candidates consistent with its product development and regulatory expertise.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 11, 2017